EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain–Barré Syndrome?

Enoch Kang, Muharrem Yunce, Yigit Baykara iD

Journal of Clinical Apheresis · 2026

DOI: 10.1002/jca.70148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Apheresis, 2026. Verfasst von Enoch Kang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Arizona, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, Receptors, Fc, Histocompatibility Antigens Class I, Blood Component Removal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the available treatment modalities such as intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE), many Guillain–Barré Syndrome (GBS) patients suffer from incomplete recovery and persistent paralysis. This paper evaluates the potential of targeting the neonatal fragment crystallizable receptor to reduce pathogenic immunoglobulin G (IgG) as a novel therapeutic approach. By reviewing current clinical evidence including data from 10 recent case reports and case series across various GBS presentations, we found that FcRn inhibitors such as efgartigimod consistently led to significant motor recovery even in refractory cases where standard treatments had already failed. Unlike broad immunosuppression, this mechanism specifically targets IgG degradation while sparing other immunoglobulin classes. Our analysis suggests that FcRn inhibition is a promising and clinically viable strategy that complements the current treatment modalities for management of GBS and GBS variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Guillain-Barre SyndromeReceptors, FcHistocompatibility Antigens Class IBlood Component RemovalHumansImmunoglobulin GPlasma ExchangeImmunoglobulins, IntravenousCentrifugation

Stichwörter der Autor:innen

FcRn inhibitorGuillain–Barré syndromeefgartigimod

Substanzen

Receptors, FcFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Department of Pathology, University of Arizona, Tucson, Arizona, USA.
  • Department of Pathology, Stanford University, Palo Alto, California, USA.

ORCID-Profile: Yigit Baykara

Zitieren

APA

Kang, E., Yunce, M., & Baykara, Y. (2026). Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain–Barré Syndrome?. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70148

Vancouver

Kang E, Yunce M, Baykara Y. Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain–Barré Syndrome?. Journal of Clinical Apheresis. 2026. doi:10.1002/jca.70148

BibTeX
@article{Kang2026,
  author = {Kang, Enoch and Yunce, Muharrem and Baykara, Yigit},
  title = {Beyond the Centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain–Barré Syndrome?},
  journal = {Journal of Clinical Apheresis},
  year = {2026},
  doi = {10.1002/jca.70148}
}
Kostenlos starten →